# 2411: Poolbeg Pharma: What US Payers Really Said

Page: https://stenobird.com/podcast/the-vox-markets-podcast-3914537/2411-poolbeg-pharma-what-us-payers-really-said
Text version: https://stenobird.com/podcast/the-vox-markets-podcast-3914537/2411-poolbeg-pharma-what-us-payers-really-said.md
Podcast: [The Vox Markets Podcast](https://stenobird.com/podcast/the-vox-markets-podcast-3914537)
Published: 2026-06-03T06:17:10+00:00
Episode link: https://audioboom.com/posts/8911222
Audio file: https://dts.podtrac.com/redirect.mp3/audioboom.com/posts/8911222.mp3?modified=1780467497&sid=5051662&source=rss
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-vox-markets-podcast-3914537/episodes/2411-poolbeg-pharma-what-us-payers-really-said
Duration seconds: 881

## Resource

Watch on YouTube Independent US payer research commissioned by Poolbeg Pharma shows strong commercial backing for POLB 001 — a first-in-class preventative for cancer immunotherapy-induced CRS. Chris from Acumentis Global on what payers said, and what it means for the commercial opportunity ahead.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-vox-markets-podcast-3914537/episodes/2411-poolbeg-pharma-what-us-payers-really-said/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-vox-markets-podcast-3914537/2411-poolbeg-pharma-what-us-payers-really-said.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.